Home LiteratureArticle Details
PMID: 7897409 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

Survival and cause of death in a cohort of patients with parkinsonism: possible clues to aetiology?

Journal of neurology, neurosurgery, and psychiatry ·Vol. 58 ·No. 3 ·1995-03-00 ·Pages 293-9

Ben-Shlomo Y, Marmot MG

Abstract

Most previous studies that have examined the survival of patients with parkinsonism have recruited them from specialist centres. No previous study has ever reported cause specific mortality. We report on the mortality of a cohort of 220 parkinsonian patients recruited between 1970 and 1972 from 40 primary health care practices all over England and Wales and matched to 421 controls. At 20 years of follow up, 195 cases (88.6%) and 295 controls (70.1%) were no longer alive (P < 0.001). The median age at death for cases was 77.6 (range 53.8-97.3) and 83.5 (range 55.0-100.1) for controls (P < 0.001). The all cause hazard ratio for cases compared with controls was 2.6 (95% confidence interval (95% CI) 2.2-3.2) controlling for age, sex, and geographical region. There was little difference between men and women. Differences for cause specific mortality also emerged. Both ischemic heart disease (2.3, 95% CI 1.5-3.4) and cerebrovascular disease (3.6, 95% CI 2.2-6.1) showed significantly increased hazard ratios. Possible reasons for these findings are discussed in terms of (a) competing causes of death, (b) a secondary effect of drug treatment, and (c) common aetiological factors for both parkinsonism and cardiovascular disease.

MeSH Terms
Aged Aged, 80 and over Case-Control Studies Cause of Death Comorbidity England/epidemiology Female Follow-Up Studies Humans Levodopa/therapeutic use Male Middle Aged Parkinson Disease/complications,drug therapy,etiology,mortality Proportional Hazards Models Survival Rate Wales/epidemiology
Chemicals
Levodopa
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Ben-Shlomo Y
Department of Epidemiology and Public Health, University College, London Medical School, UK.
Marmot M G
References (40)
40 references, click to expand
  1. The prevalence, natural history and dementia of Parkinson's disease.
    Brain. 1966 Sep;89(3):429-48 PMID: 5921126
  2. ARTERIOSCLEROSIS IN PARKINSONISM.
    J Neurol Neurosurg Psychiatry. 1964 Jun;27:237-40 PMID: 14175292
  3. Epidemiologic studies of Parkinson's disease. 3. A community-based survey.
    Am J Epidemiol. 1972 Oct;96(4):242-54 PMID: 5074681
  4. Mortality among Parkinson patients treated with L-dopa combined with a decarboxylase inhibitor.
    Eur Neurol. 1976;14(5):321-8 PMID: 949985
  5. Present morality in parkinson's disease: the ratio of observed to expected deaths with a method to calculate expected deaths.
    J Neural Transm. 1976;38(3-4):259-69 PMID: 956812
  6. Arteriosclerosis, heredity, and some previous infections in the etiology of Parkinson's disease. A case-control study.
    Clin Neurol Neurosurg. 1976;79(1):46-56 PMID: 1009713
  7. Levodopa in Parkinson disease: a long-term appraisal of mortality.
    Ann Neurol. 1978 Feb;3(2):116-8 PMID: 418738
  8. Long-term responses of Parkinson's disease to levodopa therapy.
    J Neural Transm Suppl. 1980;(16):149-56 PMID: 6776234
  9. Effect of L-dopa on course of Parkinson's disease.
    Lancet. 1984 Jul 28;2(8396):211-2 PMID: 6146763
  10. Epidemiology of parkinsonism: incidence, classification, and mortality.
    Ann Neurol. 1984 Sep;16(3):278-82 PMID: 6333204
  11. The autopsy as a measure of accuracy of the death certificate.
    N Engl J Med. 1985 Nov 14;313(20):1263-9 PMID: 4058507
  12. Parkinson's disease in the district of the Northampton Health Authority, United Kingdom. A study of prevalence and disability.
    Acta Neurol Scand. 1985 Oct;72(4):363-79 PMID: 4082901
  13. Parkinson's disease in a Scottish city.
    Br Med J (Clin Res Ed). 1986 Feb 22;292(6519):534-6 PMID: 2936423
  14. Cigarette smoking and Parkinson's disease.
    Neurology. 1986 Nov;36(11):1490-6 PMID: 3531917
  15. Referral bias in multiple sclerosis research.
    J Clin Epidemiol. 1988;41(2):187-92 PMID: 3335884
  16. Effect of age at onset on progression and mortality in Parkinson's disease.
    Neurology. 1989 Sep;39(9):1187-90 PMID: 2771070
  17. Follow-up study of early-life protective and risk factors in Parkinson's disease.
    Mov Disord. 1990;5(1):66-70 PMID: 2296261
  18. Effects of coronary risk reduction on the pattern of mortality.
    Lancet. 1990 Feb 3;335(8684):275-7 PMID: 1967732
  19. Mortality associated with early and late levodopa therapy initiation in Parkinson's disease.
    Neurology. 1990 Feb;40(2):265-9 PMID: 2300246
  20. An examination of male-female differences in progression and mortality of Parkinson's disease.
    Neurology. 1990 May;40(5):763-6 PMID: 2330103
  21. Parkinson's disease in Aberdeen: survival after 3.5 years.
    Acta Neurol Scand. 1990 Apr;81(4):294-9 PMID: 2360395
  22. Hypotensive effect of long-term levodopa in patients with Parkinson's disease.
    Eur Neurol. 1990;30(4):194-9 PMID: 2209672
  23. Stroke and its modification in Parkinson's disease.
    Stroke. 1990 Oct;21(10):1395-9 PMID: 2219202
  24. Mortality and causes of death in idiopathic Parkinson's disease: results from the Aberdeen whole population study.
    Scott Med J. 1990 Dec;35(6):173-5 PMID: 2077649
  25. Mortality in a cohort of patients with schizophrenia: a record linkage study.
    Can J Psychiatry. 1991 May;36(4):239-45 PMID: 1868416
  26. Effect of L-dopa in young patients with hypertension.
    Angiology. 1991 Sep;42(9):691-5 PMID: 1928809
  27. How independent are "independent" effects? Relative risk estimation when correlated exposures are measured imprecisely.
    J Clin Epidemiol. 1991;44(11):1223-31 PMID: 1941017
  28. Is there a J curve distribution for diastolic blood pressure?
    Clin Exp Hypertens A. 1992;14(1-2):139-49 PMID: 1541033
  29. Serum levels of alpha-tocopherol (vitamin E) in Parkinson's disease.
    Neurology. 1992 May;42(5):1064-6 PMID: 1579230
  30. What features improve the accuracy of clinical diagnosis in Parkinson's disease: a clinicopathologic study.
    Neurology. 1992 Jun;42(6):1142-6 PMID: 1603339
  31. Mortality in DSM-IIIR schizophrenia.
    Schizophr Res. 1992 Jul;7(2):109-16 PMID: 1515371
  32. Bromocriptine lessens the incidence of mortality in L-dopa-treated parkinsonian patients: prado-study discontinued.
    Eur J Clin Pharmacol. 1992;43(4):357-63 PMID: 1451713
  33. New insights into the cause of Parkinson's disease.
    Neurology. 1992 Dec;42(12):2241-50 PMID: 1461374
  34. Vitamin E consumption and the risk of coronary heart disease in men.
    N Engl J Med. 1993 May 20;328(20):1450-6 PMID: 8479464
  35. Smoking and Alzheimer's disease: protective effect or differential survival bias?
    Lancet. 1993 Sep 25;342(8874):793-4 PMID: 8103882
  36. Levodopa therapy and survival in idiopathic Parkinson's disease: Olmsted County project.
    Neurology. 1993 Oct;43(10):1918-26 PMID: 8413948
  37. Death certification after a diagnosis of presenile dementia.
    J Epidemiol Community Health. 1993 Aug;47(4):293-7 PMID: 8228765
  38. Smoking and neurogenerative diseases.
    Lancet. 1993 Nov 13;342(8881):1239 PMID: 7901555
  39. [Parkinsonism and cancer].
    Union Med Can. 1963 Feb;92:169-74 PMID: 13966497
  40. Parkinsonism: onset, progression and mortality.
    Neurology. 1967 May;17(5):427-42 PMID: 6067254
Article Info
Journal
Journal of neurology, neurosurgery, and psychiatry
Abbr.
J Neurol Neurosurg Psychiatry
ISSN
0022-3050
Published
1995-03-00
Pages
293-9
Language
English
Region
England
NLM ID
2985191R
PMCID
PMC1073364
Subset
IM
Grants
Medical Research Council · G8802774 · United Kingdom
Wellcome Trust · United Kingdom
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com